
Vigil Neuroscience (VIGL) Stock Forecast & Price Target
Vigil Neuroscience (VIGL) Analyst Ratings
Bulls say
Vigil Neuroscience Inc is positioned favorably due to its innovative approach in developing therapeutics targeting neurodegenerative diseases, particularly highlighted by promising data from the VG-3927 program, which showed a notable dose-dependent reduction in sTREM2 levels. The company has an exclusive collaboration with Sanofi, which emphasizes confidence in Vigil's technology and potential, alongside its robust Phase I clinical data that may attract further partnerships for commercialization. Additionally, Vigil is trading at a negative $25 million enterprise value, indicating significant upside potential as positive clinical outcomes could bolster stock performance and investor interest.
Bears say
Vigil Neuroscience Inc has experienced significant stock pressure, with shares declining by 26% following the ALEC TREM2 data readout, reflecting concerns over the company's performance and future prospects. The company reported a substantial net loss of $23.8 million for 4Q24, resulting in a GAAP EPS of $(0.57), which fell short of consensus expectations. Additionally, an increased valuation discount rate of 35% has led to a downward adjustment in the company's valuation target, raising concerns about its ability to meet commercial execution and market expectations.
This aggregate rating is based on analysts' research of Vigil Neuroscience and is not a guaranteed prediction by Public.com or investment advice.
Vigil Neuroscience (VIGL) Analyst Forecast & Price Prediction
Start investing in Vigil Neuroscience (VIGL)
Order type
Buy in
Order amount
Est. shares
0 shares